Circulating cytokines present in the serum of peripheral arterial disease patients induce endothelial dysfunction

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 1, 2012, Pages 67-79

  Botti, C ^a   Maione, C ^a   Dogliotti, G ^b   Russo, P ^a   Signoriello, G ^a   Molinari, A M ^a   Corsi, M M ^b,c   Sica, V ^a   Cobellis, Gilda ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Cytokines; Diabetes; Inflammation; Peripheral arterial disease

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CAPILLARY TUBE; CELL GROWTH; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SERUM; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CELL HYPOXIA; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; EPIDERMAL GROWTH FACTOR; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859894109     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 2010; 85(7):678-92.
2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Rutherford RB; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 2007; 26:81-157.
3. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71(3):510-15. (Pubitemid 15133809)
4. Selvin E, Hirsch AT. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. Atherosclerosis 2008; 201(2):425-33.
5. MacGregor AS, Price JF, Hau CM, Lee AJ, Carson MN, Fowkes FG. Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease: The Edinburgh Artery Study. Diabetes Care 1999; 22(3):453-8. (Pubitemid 29106904)
6. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation 2004; 109:2993-9.
7. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45(9):1449-57. (Pubitemid 40615617)
8. Pate M, Damarla V, Chi DS, Negi S, Krishnaswamy G. Endothelial cell biology: role in the inflammatory response. Adv Clin Chem 2010; 52:109-30.
9. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11(2):98-107.
10. Isner JM. Tissue responses to ischemia: local and remote responses for preserving perfusion of ischemic muscle. J Clin Invest 2000; 106(5):615-9.
11. Lamalice L, Le Boeuf F, Huot JL. Endothelial cell migration during angiogenesis. Circ Res 2007; 100(6):782-94. (Pubitemid 46555683)
12. Cobellis G, Silvestroni A, Lillo S, et al. Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant 2008; 42(10):667-72.
13. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59(7):1592-8. (Pubitemid 29160131)
14. Jeganathan VS. Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol 2011; 12(3):369-72.
15. Bouchentouf M, Forner K, Cuerquis J, et al. A novel and simplified method of culture of human blood derived early endothelial progenitor cells for the treatment of ischemic vascular disease. Cell Transplant 2011; 20(9):1431-43.
16. Ferguson LR, Huebner C, Petermann I, Gearry RB, Barclay ML, Demmers P, McCulloch A, Han DY. Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World J Gastroenterol 2008; 14(29):4652-61.
17. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signalling. Cell Death Differ 2003; 10(1):45-65.
18. Codullo V, Baldwin HM, Singh MD, et al. An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis 2011; 70(6):1115-21.
19. Maus U, Henning S, Wenschuh H, Mayer K, Seeger W, Lohmeyer J. Role of endothelial MCP-1 in monocyte adhesion to inflamed human endothelium under physiological flow. Am J Physiol Heart Circ Physiol 2002; 283(6):2584-91.
20. Schoenborn JR, Wilson CB. Regulation of Interferon-γ during innate and adaptive immune responses. Adv Immunol 2007; 96:41-101. (Pubitemid 350018717)
21. Roller RE, Renner W, Dorr A, Pilger E, Schnedl WJ. Oxidative stress and increase of vascular endothelial growth factor in plasma of patients with peripheral arterial occlusive disease. Thromb Haemost 2001; 85(2):368. (Pubitemid 32140586)
22. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1 in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci 2002; 102(2):187-94. (Pubitemid 34185046)
23. Sandri M, Beck EB, Adams V, et al. Maximal exercise, limb ischemia, and endothelial progenitor cells. Eur J Cardiovasc Prev Rehabil 2011; 18(1):55-64.
24. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Physiol Heart Circ Physiol 2010; 298(6):2174-91.
25. Ligresti G, Aplin AC, Zorzi P, Morishita A, Nicosia RF. Macrophage-derived tumor necrosis factor-alpha is an early component of the molecular cascade leading to angiogenesis in response to aortic injury. Arterioscler Thromb Vasc Biol 2011; 31(5):1151-9.
26. Alagappan VK, McKay S, Widyastuti A, Garrelds IM, Bogers AJ, Hoogsteden HC, Hirst SJ, Sharma HS. Proinflammatory cytokines upregulate mRNA expression and secretion of vascular endothelial growth factor in cultured human airway smooth muscle cells. Cell Biochem Biophys 2005; 43(1):119-29. (Pubitemid 41095279)
27. Jung K, Lee D, Lim HS, Lee SI, Kim YJ, Lee GM, Kim SC, Koh GY. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem 2011; 286(16):14410-8.
28. Menasché P. Cell therapy for peripheral arterial disease. Curr Opin Mol Ther 2010; 12(5):538-45.
29. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011; 53(2):445-53.
30. English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 2010; 7(4):431-42.
31. Kodama K, Nishigami K, Sakamoto T, Sawamura T, Hirayama T, Misumi H, Nakao K. Tight heart rate control reduces secondary adverse events in patients with type B acute aortic dissection. Circulation 2008; 118(14):167-70.